Other
|

Preclinical development of a nasal spray based on an immunostimulatory RNA in lipid nanoparticles for early treatment and broad-spectrum prophylaxis of viral respiratory infections

Institution: Institute of Clinical Chemistry and Clinical Pharmacology (University of Bonn, Bonn University Hospital, Prof. Gunther Hartmann) Department of Pharmacy (Ludwig Maximilian University of Munich, Prof. Olivia Merkel)
Applicant: Dr. Christine Wuebben & Dr. Simone Carneiro
Funding line:
Translational Research
Coldex specifically activates the innate antiviral immune defense locally in the nose. This mechanism provides effective protection against virus-related respiratory infections.
Coldex specifically activates the innate antiviral immune defense locally in the nose. This mechanism provides effective protection against virus-related respiratory infections.
(© University Hospital Bonn, Coldex)

In 2021, SARS-CoV-2 infections, as well as other lower respiratory tract infections were the leading cause of death worldwide. While effective antibiotics are available for the treatment of bacterial infections, therapeutic options for virus-related respiratory diseases are limited and mostly symptomatic. 

In a joint project between the University Hospital Bonn and Ludwig Maximilian University in Munich, the scientists are developing a novel approach to antiviral defense. Using an RNA activator encapsulated in lipid nanoparticles, they mimic a viral attack and activate the body's innate antiviral defense mechanisms by activating the immune receptor RIG-I. Viruses cannot infect the activated cells or spread in the body.

With the regulatory consulting funding, the scientists will prepare the necessary preclinical study plan to enable the timely initiation of Phase I development.